(rating upgraded on 12-20-06 from 4)
Initiating Date: 09-16-05
Initiating Price: $3.41
12-18 Month Price Target: $8.50
Pressure BioSciences, Inc ("PBIO") is a West Bridgewater, Massachusetts based medical technology company focused on the design, development and marketing of pressure cycling technology (PCT), a novel technology with multiple potential applications, including the extraction of nucleic acid and proteins from cells and tissues. More specifically, the company's cycling technology uses an instrument that is capable of cycling pressure between ambient and high levels at controlled temperatures to rapidly and repeatedly control the interactions of biomolecules. PCT utilizes a Barocycler™ instrument and disposable PULSE™ Tubes to release nucleic acids and proteins from plant/animal cells and tissues, as well as other organisms that are not easily disrupted by standard chemical and physical methods. PBIO believes that their patented and proprietary pressure cycling technology employs a unique approach that has the potential for broad applications in a number of established and emerging fields, including genomics, proteomics, drug discovery and development, protein purification, pathogen inactivation, immunodiagnostics, food safety, protein re-folding and disaggregation, and DNA sequencing.
The company holds a number of patents encompassing these potential applications across a variety of medical research disciplines in the healthcare space. From my perspective, the attractive thing about the company's technology(s) is that I view it as an enabler to a number of growing and highly promising medical endeavors. Typically, high-risk high return scenarios wherein considerable amounts of research and development capital are expended often in the pursuit of therapies or treatments that ultimately fail to successfully mitigate the ailments they seek to address characterize biotech and/or medical research investments. Those scenarios are further burdened by onerous regulation and approval processes by entities such as the U.S. Food and Drug Administration, whereby even successful therapies and approaches can involve long periods of time to come to fruition. In that regard, I think that technologies that enable the enterprises and processes pursuing new/novel treatment regimens may offer considerable opportunity as participants in that growth without some of the risks typically associated with the industry, such as failed efficacy or toxicity results, as well as long regulatory approval cycles. In other words, PBIO has a novel, patented solution, which may help in the research and development of a myriad of cutting edge medical based applications, but requires no special approval, and its success is not based on the ultimate efficacy or safety of any single product or clinical trial result. It is perhaps a biotech "play" without some of the biotech related risks.
DISCLAIMER STATEMENT
The information contained in this report has been written by David Lavigne of EdgeWater Research Partners LLC ("Edgewater") and has been derived from sources considered reliable, but cannot be guaranteed by us. Edgewater and Lavigne are not aware of any material conflict of interest known at the time of the publication of this report. Financial projections and estimates herein represent our independent analysis based upon information in conjunction with the Company's publicly available financial statements. Edgewater and Lavigne may maintain positions in the securities referenced, which may change at any time without notice. Edgewater does not receive fees, warrants or any other compensation from issuers in connection with its research. It does however, encourage issuers and it representatives to subscribe to Edgewater's research, and from time to time, issuers and or their representatives may also purchase individual copies of Edgewater's research products. Edgewater and Lavigne may own options, rights or warrants to purchase any of the securities of the Company. This report is for informational purposes only and is not to be construed as specific investment advice or recommendations, nor as an offer to sell or a solicitation of an offer to buy any securities. The securities referenced are speculative in nature and may not be suitable for your specific investment objective. For specific investment advice or recommendations, please consult with your investment representative.
.
